TCM
PACB icon

Teza Capital Management’s Pacific Biosciences PACB Stock Holding History

Teza Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,706
Closed -$40.1K – 709
2024
Q1 		$40.1K Buy
+10,706
New +$62.7K 0.01% 545
2017
Q2 		– Sell
-29,569
Closed -$153K – 265
2017
Q1 		$153K Buy
+29,569
New +$145K 0.04% 450

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Teza Capital Management's PACB Position: Q2 2024 in Review

Teza Capital Management sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 10,706 shares — an estimated $40.1K sold.

Teza Capital Management first reported a position in PACB in Q1 2017 and held it in 2 quarters. The position peaked at $153K in Q1 2017. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Teza Capital Management reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Teza Capital Management sold 10,706 Pacific Biosciences shares in Q2 2024, an estimated $40.1K.
  • Teza Capital Management first reported a position in Pacific Biosciences in Q1 2017 and held it in 2 quarters.
  • Teza Capital Management's Pacific Biosciences position peaked at $153K in Q1 2017.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Teza Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.